Advice
In the absence of a submission from the holder of the marketing authorisation:
ramucirumab (Cyramza®) is not recommended for use within NHSScotland.
Indication under review: in combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice614KB (PDF)
Medicine details
- Medicine name:
- ramucirumab (Cyramza)
- SMC ID:
- SMC2291
- Indication:
In combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations
- Pharmaceutical company
- Eli Lilly and Company Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 June 2021